Evaluation of the complex approach effectiveness of atrophic colpitis treatment in menopausal aged women from the pathogenetic view
DOI:
https://doi.org/10.18370/2309-4117.2022.66.26-31Keywords:
atrophic colpitis, marker of collagen synthesis, magnesium, menopause, CO2 laserAbstract
Objectives: to determine the status of connective tissue and ionized magnesium value before and after complex treatment of atrophic colpitis with the CO2 laser in menopausal women.
Materials and methods. 160 women with atrophic colpitis took part in this prospective study and were divided into three groups depending on the therapy. The main group included 55 patients who underwent CO2 laser therapy. The comparison group included 40 women who underwent CO2 laser therapy and local hormonal treatment with suppositories containing estriol and magnesium saturation by magnesium lactate dihydrate. The control group consisted of 65 women who received only suppositories containing estriol. The duration of treatment was 12 months. In addition to general clinical studies, markers of collagen synthesis (Total PINP, Total PІІІNP), collagen resorption marker (Pyriliks-D), as well as the ionized magnesium value in blood serum were determined in all patients.
Results. A significant increase and steady retention at the physiological level of the average value of the Total PINP in the comparison group was revealed. The average level of the Total PIІІNP in patients of this group underwent a significant decrease and remained steadily at the upper limit of the physiological norm. A significant decrease and stable retention at the physiological level of the Pyriliks-D was noted in the comparison group against the background of the proposed therapy. Correction of magnesium status in the comparison group leads to a reliable and stable increase in the Mg+ ions concentration in blood serum.
Conclusions. The inclusion CO2 laser in combination with local hormonal therapy and long-term correction of mineral metabolism in the treatment of the comparison group led to the stable normalization and prolonged retention at the physiological level for 12 months of the procollagen type I N-terminal propeptide, procollagen type III N-terminal propeptide, collagen resorption marker Pyriliks-D and a significant increase in magnesium concentration. This is confirms the effectiveness of the proposed complex.
References
- Apolihina, I.A, Gorbunova, E.A. “Clinical and morphological aspects of vulvovaginal atrophy.” Medical Council 9 (2014): 110–7.
- Apolihina, I.A, Piskunova, E.V., Gorbunova, E.A., Saidova, A.S. “Aesthetic gynecology – a new direction in gynecology.” Effective pharmacotherapy 13 (2017): 34–8.
- Glazunova, A.V., Jureneva, S.V., Ermakova, E.I. “Vaginal atrophy.” Obstetrics and gynecology 2 (2014): 21–6.
- Zhabchenko, Р.A., Magomedov, O.M., Oleshko, V.F. “The role of connective tissue and some trace elements in the development of isthmic-cervical insufficiency.” Collection of scientific works of the Association of Obstetricians and Gynecologists of Ukraine. Kyiv: Polygraf plus 2.38 (2016): 188–93.
- Ilyina, I.Y., Dobrohotova, Y.E., Venediktova, M.G., et al. “Effective correction of genitourinary menopausal syndrome by laser fractional ablation.” RMJ Mother & Child 5.1 (2018): 4–8.
- Kalugina, L.V., Tatarchuk, T.F., Shakalo, I.N., et al. “Nonspecific vulvovaginitis of mixed etiology: local treatment – therapy of choice.” Reproductive endocrinology 1.27 (2016): 94–100.
- Kuznetsova, I.V., Chushkov, Y.V., Ishchenko, A.I. “The role of local use of estriol in optimizing the outcomes of surgical treatment of genital prolapse in peri- and postmenopausal patients.” Obstet Gynecol 19 (2015): 2–6.
- Ministry of Health of Ukraine. Order from 17.06.2022 № 1039 “Menopausal disorders and other disorders in the perimenopausal period”.
- Arroyo, C. “Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women.” Int J Womens Health 28.9 (2017): 591–5. DOI: 10.2147/IJWH.S136857
- Arunkalaivanan, A., Kaur, H., Onuma, O. “Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence.” Int Urogynecol J 28.5 (2017): 681–5. DOI: 10.1007/s00192-017-3282-y
- Athanasiou, S., Pitsouni, E., Falagas, M.E., et al. “CO2-laser for the genitourinary syndrome of menopause. How many laser sessions?” Maturitas 104 (2017): 24–8. DOI: 10.1016/j.maturitas.2017.07.007
- Behnia-Willison, F., Sarraf, S., Miller, J., et al. “Safety and long-term efficacy of fractional CO (2) laser treatment in women suffering from genitourinary syndrome of menopause.” Eur J Obstet Gynecol Reprod Biol 213 (2017): 39–44. DOI: 10.1016/j.ejogrb.2017.03.036
- Calleja-Agius, J., Brincat, M.Р “The urogenital system and the menopause” Climacteric 18.1 (2015): 18–22. DOI: 10.3109/13697137.2015.1078206
- Faubion, S.S., Larkin, L.C., Stuenkel, C.A., et al. “Management of genitourinary syndrome of menopause in women with high risk for breast cancer: consensus recommendations from The North American Monopause Society and the International Society for the Study of Women’s Sexual Care.” Menopause 25.6 (2018): 1–13. DOI: 10.1097/GME.0000000000001121
- Eder, S.E. “Long-Term Safety and Efficacy of Fractional CO2 Laser Treatment in Post-Menopausal Women with Vaginal Atrophy.” Laser Ther 28 (2019): 103–109. DOI: 10.5978/islsm.28_19-OR-06
- Edwards, D., Panay, N. “Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition.” Climacteric 19.2 (2016): 151–61.
- Gambacciani, M., Palacios, S. “Laser therapy for the restoration of vaginal function.” Maturitas 99 (2017): 10–15. DOI: 10.1016/j.maturitas.2017.01.012
- Hutchinson-Colas, J., Segal, S. “Genitourinary syndrome of menopause and the use of laser therapy.” Maturitas 82.4 (2015): 342–5. DOI: 10.1016/j.maturitas.2015.08.001
- Samuels, J.B., Garcia, M.A. “Treatment to External Labia and Vaginal Canal With CO2 Laser for Symptoms of Vulvovaginal Atrophy in Postmenopausal Women.” Aesthetic Surgery J 39.1 (2019): 83–93. DOI: 10.1093/asj/sjy087
- Williams, N.O., Lustberg, M.B. “Time for Action: Managing of Genitourinary Syndrome of Menopaues.” J Oncol Pract 15.7 (2019): 371.DOI: 10.1200/JOP.19.00350
- Pagano, I., Gieri, S., Nocera, F., et al. “Evaluation of the CO2 Laser Therapy on Vulvo-Vaginal Atrophy (VVA) in Oncological Patients: Preliminary Results.” J Cancer Ther 8.5 (2017): 452–63. DOI: 10.4236/jct.2017.85039
- Perino, A., Calligaro, A., Forlani, F., et al. “Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser.” Maturitas 80.3 (2015): 296–301. DOI: 10.1016/j.maturitas.2014.12.006
- Nappi, R.E., Martini, E., Cucinella, L., et al. “Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Health Aging in Women.” Front Endocrinol 10 (2019): 1–11. DOI: 10.3389/fendo.2019.00561
- Rueda, C., Osorio, A.M., Avellaneda, A.C., et al. “The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.” Climacteriс 20.4 (2017): 321–30. DOI: 10.1080/13697137.2017.1329291
- Stefano, S., Stavros, A., Massimo, C. “The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol 27.6 (2015): 504–8. DOI: 10.1097/GCO.0000000000000230
- Takahashi, T.A, Johnson, K.M. “Menopause.” Med Clin North Am 99 (2015): 521–53. DOI: 10.1016/j.mcna.2015.01.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 В.О. Бенюк, В.М. Гончаренко, І.А. Усевич, В.Ф. Олешко, А.А. Момот, М.С. Пучко, Я.І. Веретельник
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.